Drug intelligence / Profile preview

Acetyldihydrocodeine

Development stage: Preclinical
Modality: Small Molecules
Administration: Oral

Overview

Acetyldihydrocodeine is a small molecule and a derivative of codeine, belonging to the class of phenanthrenic opioids. It has been studied for its potential analgesic effects and its ability to modulate morphine glucuronidation. In in vitro studies, acetyldihydrocodeine was found to be ineffective in inhibiting the synthesis of morphine-3-glucuronide (M3G) and morphine-6-glucuronide (M6G). Animal studies indicated that it possesses analgesic activity, albeit less potent than dihydrocodeinone, and exhibits a low affinity for μ opiate receptors.

Targets

MOR (Mu opioid receptor)

Beyond the preview

Go deeper on Acetyldihydrocodeine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Acetyldihydrocodeine.

Explore the full profile